Clozapine/norclozapine plasma level ratio and cognitive functioning in patients with schizophrenia spectrum disorders: a systematic review

Clozapine/norclozapine plasma level ratio and cognitive functioning in patients with schizophrenia spectrum disorders: a systematic review

Background: Extant research on cognitive functioning in treatment-resistant schizophrenia (TRS) is limited and of poor quality. Cognitive impairments in patients with schizophrenia spectrum disorders (SSD) significantly influence quality of life. In patients with TRS, clozapine (CLO) is not consiste...

Full description

Saved in:

Bibliographic Details
Main Authors:	Timo T. Moscou, Selene R. T. Veerman
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-12-01
Series:	Therapeutic Advances in Psychopharmacology
Online Access:	https://doi.org/10.1177/20451253241302603
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The effects of clinical and pharmacological factors on the ratio of clozapine to norclozapine in psychiatric patients
by: Anna Mach, et al.
Published: (2025-01-01)

Prevalence and factors associated with high risk for obstructive sleep apnea in schizophrenia spectrum disorder patients on long-term clozapine
by: Rika Rijal, et al.
Published: (2024-12-01)

A False Case of Clozapine-Resistant Schizophrenia
by: J. P. Maia-de-Oliveira, et al.
Published: (2010-01-01)

The effect of clozapine on immune-related biomarkers in schizophrenia patients
by: Lu Shao, et al.
Published: (2024-11-01)

Thinking-language Disorders Types’ of Schizophrenia Spectrum Disorders Patients
by: E.M. Smerchinskaya, et al.
Published: (2024-09-01)

Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis
by: Yun-Jung Choi
Published: (2015-01-01)

Response to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow
by: Junyu Sun, et al.
Published: (2024-12-01)

Prevalence of obsessive-compulsive symptoms in patients with schizophrenia treated with clozapine: a scoping review
by: Evelyn Moreno Tarazona, et al.
Published: (2025-01-01)

Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
by: Dhandapani Nandakumar, et al.
Published: (2023-06-01)

Response after Infection-Associated Rise in Clozapine Levels in Treatment-Resistant Schizoaffective Disorder
by: Nina H. Grootendorst-van Mil, et al.
Published: (2018-01-01)

Augmentation of Antipsychotic Medications with Low-Dose Clozapine in Treatment-Resistant Schizophrenia—Case Reports and Discussion
by: Zoe Harrison, et al.
Published: (2021-01-01)

Successful utilization of clozapine for a patient with treatment‐resistant schizophrenia after recurrent violent behavior
by: Rikuto Christopher Shinohara, et al.
Published: (2024-09-01)

Schizophrenia spectrum disorders in India: A population-based study
by: Prakyath Ravindranath Hegde, et al.
Published: (2023-12-01)

Plasma vitamin levels and pathway analysis in boys with autism spectrum disorders
by: Lili Zhang, et al.
Published: (2024-12-01)

Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: A population cohort study.
by: Yuqi Hu, et al.
Published: (2024-12-01)

Multimodal prediction of the need of clozapine in treatment resistant schizophrenia; a pilot study in first-episode psychosis
by: Jonatan M. Panula, et al.
Published: (2024-12-01)

Molecular physiology unlocks the mystery that relates cognitive impairment with the retina in schizophrenia and autism spectrum disorders: a perspective review
by: Sarah Al-Mazidi, et al.
Published: (2024-11-01)

Corrigendum to “The effect of clozapine on immune-related biomarkers in schizophrenia patients” [Brain Res. Bull. 218 (2024) 111104]
by: Lu Shao, et al.
Published: (2024-12-01)

Clozapine for Treatment-Resistant Disruptive Behaviors in Youths With Autism Spectrum Disorder Aged 10-17 Years: Protocol for an Open-Label Trial
by: André Luiz Schuh Teixeira da Rosa, et al.
Published: (2025-01-01)

Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review
by: Abigail Gee, et al.
Published: (2025-01-01)

Comparison of Plasma Neurosteroid and Prolactin Levels in Patients with Schizophrenia and Healthy Individuals
by: Forough Riahi, et al.
Published: (2016-01-01)

The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
by: Hélène Verdoux, et al.
Published: (2025-01-01)

Predictors of clozapine efficacy in treatment-resistant schizophrenia: A cross-sectional analysis of sociodemographic, clinical, biochemical, and electrophysiological EEG changes
by: Sumaila Asif, et al.
Published: (2024-11-01)

Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy
by: Vivekananda Rachamallu, et al.
Published: (2017-01-01)

A Case of Clozapine-Induced Myocarditis in a Young Patient with Bipolar Disorder
by: Ronny Cohen, et al.
Published: (2015-01-01)

A rare event of late agranulocytosis during clozapine use in schizophrenia and the importance of monitoring vitamin B12 levels in patients with severe psychiatric conditions: a case report
by: Alessandra Faggion Mocellin, et al.
Published: (2024-12-01)

The Association of Serum Lactoferrin Level with Psychological Symptoms, Cognition, and Executive Function in Schizophrenia Patients
by: Niloufar Mahdavi Hezaveh, et al.
Published: (2024-12-01)

Uncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics
by: Aitor Villate, et al.
Published: (2024-12-01)

Investigation of choroid plexus variability in schizophrenia-spectrum disorders—insights from a multimodal study
by: Vladislav Yakimov, et al.
Published: (2024-12-01)

Depressive and Negative Symptoms in the Early and Established Stages of Schizophrenia: Integrating Structural Brain Alterations, Cognitive Performance, and Plasma Interleukin 6 Levels
by: Fabiana Corsi-Zuelli, et al.
Published: (2025-03-01)

Loxapine and Cyproheptadine Combined Limit Clozapine Rebound Psychosis and May Also Predict Clozapine Response
by: Lila Aboueid, et al.
Published: (2016-01-01)

Experience with and attitude toward clozapine use among patients receiving clozapine on long term and their caregivers
by: Sandeep Grover, et al.
Published: (2023-11-01)

Association of polygenic liabilities for schizophrenia and bipolar disorder with educational attainment and cognitive aging
by: Chi-Shin Wu, et al.
Published: (2024-11-01)

Cognitive functioning and functional ability in women with schizophrenia and homelessness
by: Jayakumar Menon, et al.
Published: (2025-03-01)

CORRELATION BETWEEN COGNITIVE FUNCTION AND SERUM LEVELS OF TUMOR NECROSIS ALPHA (TNF-α) IN SCHIZOPHRENIA
by: Eldi Sauma, et al.
Published: (2024-02-01)

Clozapine-induced hypertension: A paradox
by: Hamza Hussain, et al.
Published: (2024-12-01)

Persistent Tachycardia in a Patient on Clozapine
by: Samuel Adeyemo, et al.
Published: (2020-01-01)

Severe Relapsing Clozapine-Withdrawal Catatonia
by: Tarek Shahrour, et al.
Published: (2015-01-01)

Association between treatment resistance and cognitive function in schizophrenia
by: Jiaqian Sun, et al.
Published: (2024-10-01)

Digital sleep phenotype and wrist actigraphy in individuals at clinical high risk for psychosis and people with schizophrenia spectrum disorders: a systematic review and meta-analysis
by: Andrea Cipriani, et al.
Published: (2025-02-01)